Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus + bifidobacterium animalis lactis
- Development stage
- Unknown
- Lead developer
- Foxland
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
lactobacillus acidophilus + bifidobacterium animalis lactis is an oral probiotic combination composed of live bacterial cultures of *Lactobacillus acidophilus* and *Bifidobacterium animalis* subsp. *lactis*. It has been marketed as a dietary supplement for gastrointestinal and probiotic support under brand names including ReliBiotic, SureBiotic, and ProRiva, with Redmont Pharmaceuticals identified as a marketer/distributor in the provided context. Mechanistically, this microbial combination is intended to modulate the gut microbiome and host mucosal immune signaling rather than act on a single canonical drug target; preclinical literature cited in the provided context links it to attenuation of intestinal inflammatory signaling, including TLR2-mediated NF-kB and MAPK pathway modulation in intestinal epithelial cells. Human studies mentioned in the provided context include probiotic yogurt formulations containing these organisms in type 2 diabetes and maternal postpartum supplementation studies evaluating prevention of necrotizing enterocolitis in preterm infants. The product is best characterized as a probiotic nutraceutical or dietary supplement rather than an FDA-approved pharmaceutical drug.
- Brand names
- ReliBioticSureBioticProRiva
- Other names
- Lactobacillus acidophilus + Bifidobacterium animalis lactisLactobacillus acidophilus + Bifidobacterium lactis
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on lactobacillus acidophilus + bifidobacterium animalis lactis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus + bifidobacterium animalis lactis.